Once-daily roflumilast foam significantly improves scalp and body psoriasis in 8 weeks and was well-tolerated in adolescents ...

Adding tumor-bed biopsy to trimodality imaging after neoadjuvant chemotherapy did not reliably predict pathological complete ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to ...

(Reuters) -Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

An analysis from IQVIA found that between 2017 and 2021 the U.S. spent $260 billion on originator biologics, 2 the reference ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Amgen Inc. outperformed Wall Street’s quarterly profit estimates as it moves forward with plans to crack the ...